Review
Medicine, Research & Experimental
Grzegorz Grzesk, Bednarska Dorota, Lukasz Wolowiec, Anna Wolowiec, Joanna Osiak, Mariusz Kozakiewicz, Joanna Banach
Summary: 4 million people die from cardiovascular diseases annually in Europe due to atherosclerosis. Lowering LDL cholesterol level is the main therapeutic goal, but only 43% of statin-taking patients achieved their targets. PCSK9 inhibitors are a new group of lipid-lowering drugs that can reduce LDL-C level.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Morasa Sheikhy, Sarah J. Schrieber, Qin Sun, Victoria Gershuny, Murali K. Matta, Jane P. F. Bai, Xiulian Du, Giri Vegesna, Aanchal Shah, Kristin Prentice, Colleen Nalepinski, Issam Zineh, Yow-Ming Wang, David G. Strauss, Jeffry Florian
Summary: The FDA guidance on biosimilars development suggests that comparative clinical efficacy studies can be replaced by pharmacokinetic (PK) and pharmacodynamic (PD) similarity studies. However, there is a lack of PD comparability studies in biosimilar development, making it unclear how to plan these studies effectively.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Hui-Chun Huang, Shao-Jung Hsu, Ching-Chih Chang, Chiao-Lin Chuang, Ming-Chih Hou, Fa-Yauh Lee
Summary: Alirocumab treatment improves hyperlipidemia and systemic oxidative stress in biliary cirrhotic rats. However, it does not affect the plasma level of ox-LDL, intrahepatic inflammation and fibrosis. In addition, PCSK9 inhibition has a neutral effect on abnormal angiogenesis and hepatic encephalopathy in biliary cirrhotic rats.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Rahayu Zulkapli, Suhaila Abd Muid, Seok Mui Wang, Hapizah Nawawi
Summary: This study aimed to investigate the effects of PCSK9 inhibitors on PCSK9, targeted early atherogenesis biomarkers, and monocyte binding in stimulated human coronary artery endothelial cells (HCAEC). The results showed that PCSK9 inhibitors exerted anti-atherogenic effects by downregulating PCSK9 and early atherogenesis biomarkers, as well as significantly inhibiting monocyte adhesion to endothelial cells via the NF-kappa B and eNOS pathways. These findings suggest the potential role of PCSK9 inhibitors in preventing atherosclerosis-related complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Maciej Banach, Jose Luis Lopez-Sendon, Maurizio Averna, Bertrand Cariou, Megan Loy, Garen Manvelian, Isabela Batsu, Yann Poulouin, Daniel Gaudet
Summary: The study evaluated the real-life effectiveness of alirocumab treatment in high cardiovascular risk patients. The results showed that alirocumab treatment significantly reduced LDL-C levels in different statin intensity subgroups and prior ezetimibe therapy subgroups, with high patient adherence.
ARCHIVES OF MEDICAL SCIENCE
(2022)
Review
Cardiac & Cardiovascular Systems
Paul Guedeney, Sabato Sorrentino, Gennaro Giustino, Celine Chapelle, Silvy Laporte, Bimmer E. Claessen, Edouard Ollier, Anton Camaj, Deborah N. Kalkman, Birgit Vogel, Salvatore De Rosa, Ciro Indolfi, Benoit Lattuca, Michel Zeitouni, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Roxana Mehran, Gilles Montalescot
Summary: This study compared the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or established atherosclerotic cardiovascular disease. The results showed that there were no significant differences in efficacy endpoints between the two drugs, except for a better reduction in all-cause death with alirocumab. However, alirocumab had a higher risk of injection site reactions compared to evolocumab.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2021)
Article
Pharmacology & Pharmacy
Enchen Zhou, Zhuang Li, Hiroyuki Nakashima, Ahlam Choukoud, Sander Kooijman, Jimmy F. P. Berbee, Patrick C. N. Rensen, Yanan Wang
Summary: Accelerating lipolytic processing of VLDL by brown fat activation can further lower (V)LDL levels and reduce the risk of atherosclerosis.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Cardiac & Cardiovascular Systems
Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E. Claessen, Anton Camaj, Deborah N. Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber, Ciro Indolfi, Gilles Montalescot, George D. Dangas, Robert S. Rosenson, Stuart J. Pocock, Roxana Mehran
Summary: Treatment with alirocumab or evolocumab is associated with reduced risk of myocardial infarction, stroke, and coronary revascularization, with a favorable safety profile.
EUROPEAN HEART JOURNAL
(2022)
Article
Endocrinology & Metabolism
Jonas Ghouse, Gustav Ahlberg, Henning Bundgaard, Morten S. Olesen
Summary: This study evaluated the association between PCSK9 predicted loss-of-function (pLoF) variants and glycemic traits, hepatobiliary function, and neurocognitive traits. The results showed significant effects of PCSK9 pLoF variants on lipid and lipoprotein metabolism, but no significant associations with glycemic traits, hepatobiliary function, and neurocognitive traits.
Article
Cardiac & Cardiovascular Systems
Tahir Mahmood, Jessica Minnier, Matthew K. Ito, Qian H. Li, Andrew Koren, Ivy W. Kam, Sergio Fazio, Michael D. Shapiro
Summary: This study aimed to investigate the prevalence of discordant plasma LDL-C/Lp(a) response to the PCSK9 inhibitor alirocumab, and a high prevalence of discordant response was observed, suggesting that alirocumab may reduce Lp(a) through alternative pathways.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Cristina Barale, Elena Melchionda, Alessandro Morotti, Isabella Russo
Summary: PCSK9 plays a key role in lipoprotein metabolism and atherosclerosis, with potential cardiovascular benefits from its inhibition. Currently, anti-PCSK9 antibodies and small interfering RNA are effective therapies to reduce LDL-C levels and attenuate cardiovascular disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Medicinal
Claudia Stefanutti, Dick C. Chan, Serafina Di Giacomo, Claudia Morozzi, Gerald F. Watts
Summary: The study demonstrates that evinacumab is a safe and effective treatment for HoFH patients, leading to significant reduction in LDL-C levels, which is maintained even without LA treatment.
Article
Medicine, Research & Experimental
Juan Vicente-Valor, Xandra Garcia-Gonzalez, Sara Ibanez-Garcia, Maria Esther Duran-Garcia, Ana de Lorenzo-Pinto, Carmen Rodriguez-Gonzalez, Irene Mendez-Fernandez, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso, Maria Sanjurjo-Saez
Summary: PCSK9 inhibitors have shown to be effective and safe in treating patients with hypercholesterolemia, with factors such as female sex, lack of concomitant lipid-lowering therapy, and treatment with alirocumab potentially influencing their effectiveness. The study found that 84.6% of patients achieved therapeutic goals, with drug-related adverse events affecting a portion of participants.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Cardiac & Cardiovascular Systems
Michelle L. O'Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Jose H. Flores-Arredondo, J. Antonio G. Lopez, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine
Summary: Long-term use of evolocumab to lower LDL-C levels is associated with low rates of adverse events, which do not exceed those in the placebo group. Over time, the use of evolocumab also leads to further reduction in cardiovascular events.
Review
Cardiac & Cardiovascular Systems
Douglas L. Jennings, Lina Sultan, Jennifer Mingov, Jason Choe, Farhana Latif, Susan Restaino, Kevin Clerkin, Marlena Habal, Paolo C. Colombo, Melana Yuzefpulskaya, Gabriel Sayer, Nir Uriel, William L. Baker
Summary: Coronary allograft vasculopathy (CAV) is a common problem in heart transplant recipients, and high LDL cholesterol is a major risk factor. Many patients cannot tolerate statin medications after transplantation, and there is limited data on alternative treatments. This study conducted a systematic review and meta-analysis to evaluate the safety and efficacy of PCSK9 inhibitors (PCSK9i) after heart transplantation. The results showed that PCSK9i use significantly reduced LDL cholesterol levels and had a favorable safety profile. Further studies with larger cohorts are needed to confirm these findings.
HEART FAILURE REVIEWS
(2023)
Article
Hematology
Charles J. Glueck, Vybhav Jetty, Naila Goldenberg, Parth Shah, Ping Wang
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2017)
Article
Hematology
Charles J. Glueck, Marloe Prince, Niravkumar Patel, Jaykumar Patel, Parth Shah, Nishi Mehta, Ping Wang
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2016)
Article
Medicine, General & Internal
Charles J. Glueck, Naila Goldenberg, Ping Wang
JOURNAL OF INVESTIGATIVE MEDICINE
(2018)
Article
Biochemistry & Molecular Biology
Parth Shah, Charles J. Glueck, Naila Goldenberg, Sarah Min, Chris Mahida, Ilana Schlam, Matan Rothschild, Ali Huda, Ping Wang
LIPIDS IN HEALTH AND DISEASE
(2017)
Article
Pharmacology & Pharmacy
Charles J. Glueck, Alan Brown, Anne C. Goldberg, James M. McKenney, Louis Kantaros, John Stewart, Joseph Elassal, Andrew Koren
JOURNAL OF CLINICAL LIPIDOLOGY
(2018)
Review
Endocrinology & Metabolism
Charles J. Glueck, Naila Goldenberg
METABOLISM-CLINICAL AND EXPERIMENTAL
(2019)
Review
Medicine, General & Internal
Charles J. Glueck, Naila Goldenberg, Ping Wang
JOURNAL OF CLINICAL MEDICINE
(2019)
Article
Orthopedics
Charles J. Glueck, Richard A. Freiberg, Ping Wang
Article
Hematology
Alexander Milgrom, Kevin Lee, Matan Rothschild, Frini Makadia, Greg Duhon, Sarah Min, Ping Wang, Charles J. Glueck
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2018)
Article
Hematology
Matan Rothschild, Vybhav Jetty, Christopher Mahida, Ping Wang, Marloe Prince, Naila Goldenberg, Charles J. Glueck
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2017)
Article
Peripheral Vascular Disease
Vybhav Jetty, Charles J. Glueck, Kevin Lee, Naila Goldenberg, Marloe Prince, Ashwin Kumar, Michael Goldenberg, Ishan Anand, Ping Wang
VASCULAR HEALTH AND RISK MANAGEMENT
(2017)
Article
Ophthalmology
Stephan G. Dixon, Carl T. Bruce, Charles J. Glueck, Robert A. Sisk, Robert K. Hutchins, Vybhav Jetty, Ping Wang
CLINICAL OPHTHALMOLOGY
(2016)
Article
Medicine, General & Internal
Charles J. Glueck, Kevin Lee, Marloe Prince, Vybhav Jetty, Parth Shah, Ping Wang
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS
(2016)
Article
Medicine, General & Internal
Vybhav Jetty, Charles J. Glueck, Ping Wang, Parth Shah, Marloe Prince, Kevin Lee, Michael Goldenberg, Ashwin Kumar
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES
(2016)